Aspek Imunitas pada COVID-19
DOI:
https://doi.org/10.55175/cdk.v48i9.134Kata Kunci:
COVID-19, interleukin-6, interleukin-10, TNF-AlfaAbstrak
Gejala COVID-19 sangat bervariasi dari ringan hingga berat. Selain faktor komorbiditas, reaksi imun yang berbeda-beda antar pasien juga menjadi faktor yang memengaruhi berat-ringannya gejala COVID-19. Kenaikan kadar sitokin diduga menjadi faktor yang memperberat gejala COVID-19. Dalam artikel ini, akan dibahas aspek respons imun serta sitokin yang memengaruhi gejala COVID-19, serta beberapa pengobatan imunologi yang sedang diteliti untuk COVID-19.
Symptoms in COVID-19 patients vary widely from mild to severe. In addition to comorbidities, different immune reactions among patients are also a factor that affects the severity of COVID-19 symptoms. The increase in cytokine levels is thought to be a factor that aggravates the symptoms of COVID-19. In this article, we will discuss aspects of the immune response and cytokines that affect the symptoms of COVID-19, as well as some of the immunological treatments currently being studied for COVID-19.
Unduhan
Referensi
CDC. Healthcare Workers [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 May 31]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. Sn Compr Clin Med. 2020 Jun 25;1–8.
Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17–41.
Nagant C, Ponthieux F, Smet J, Dauby N, Doyen V, Besse-Hammer T, et al. A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2020 Dec;101:342–5.
Dhar SK, K V, Damodar S, Gujar S, Das M. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon. 2021 Feb;7(2):e06155.
Kwon J-S, Kim JY, Kim M-C, Park SY, Kim B-N, Bae S, et al. Factors of Severity in Patients with COVID-19: Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses. Am J Trop Med Hyg. 2020 Dec;103(6):2412–8.
Lu T, Reis BY. Internet search patterns reveal clinical course of COVID-19 disease progression and pandemic spread across 32 countries. Npj Digit Med. 2021 Feb 11;4(1):1–9.
Wang J, Zheng X, Chen J. Clinical progression and outcomes of 260 patients with severe COVID-19: an observational study. Sci Rep. 2021 Feb 4;11(1):3166.
Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, et al. Time between Symptom Onset, Hospitalisation and Recovery or Death: Statistical Analysis of Belgian COVID-19 Patients. Int J Environ Res Public Health. 2020 Oct 17;17(20).
Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. Front Immunol. 2021;12:613422.
Corticosteroids [Internet]. COVID-19 Treatment Guidelines. [cited 2021 May 31]. Available from: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/corticosteroids/
Erlina Burhan. Pedoman Tatalaksana COVID-19. 2020 Dec;
Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330.
Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clin Infect Dis. 2021;72(9):e373–81.
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307.
Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med [Internet]. 2021 Apr 9 [cited 2021 May 31]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040526/
Group PC, Yu L-M, Bafadhel M, Dorward J, Hayward G, Saville BR, et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv. 2021 Apr 12;2021.04.10.21254672.
Interleukin-6 Inhibitors [Internet]. COVID-19 Treatment Guidelines. [cited 2021 May 31]. Available from: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/interleukin-6-inhibitors/
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021;384(16):1503–16.
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384(1):20–30.
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384(16):1491–502.
Group RC, Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021 Feb 11;2021.02.11.21249258.
Interleukin-1 Inhibitors [Internet]. COVID-19 Treatment Guidelines. [cited 2021 May 31]. Available from: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/interleukin-1-inhibitors/
Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–400.
Tharaux P-L, Pialoux G, Pavot A, Mariette X, Hermine O, Resche-Rigon M, et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;9(3):295–304.
Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021 Feb 1;7(1):e001455.
Tardif J-C, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. medRxiv. 2021 Jan 27;2021.01.26.21250494.
RECOVERY Trial of COVID Treatments Stops Colchicine Arm [Internet]. Medscape. [cited 2021 May 31]. Available from: http://www.medscape.com/viewarticle/946978
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2021 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
